Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the United States, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.
Current Team (12)Update
Chief Commercial Officer
Chief Financial Officer / Chief Accounting Officer
Vice President, Global Development
Vice President, Clinical Affairs
Vice President, Global Sales
Chief Scientific Officer
Vice President, Marketing
President and CEO
Funding Rounds (6) - $97.8MUpdate
Board Members and Advisors (8)Update
Healthcare-focused Investment Group
Borealis Ventures partners closely with exceptional entrepreneurs from the earliest stages to...
Venture capital firm
Third Point Ventures is the venture capital arm of Third Point LLC, a registered investment...
Prism Ventureworks has 5 funds with $1.25 billion in investments. Their most recent fund is for...
DeNovo Ventures was formed in 2000 by seasoned investors and experienced medical device...
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates...
230 Third Avenue
Waltham, MA 02451